Abstract | INTRODUCTION: METHODS: The objective of this work was to analyze the efficacy and safety of this treatment for chylothorax after congenital heart surgery. We reviewed the records of sixteen patients with chylothorax after surgery for congenital heart disease between January 1999 and December 2007, and collected the following data: demographic information; type of surgical procedure; onset, duration and management of chylothorax and treatment; and duration of hospital stay. To analyze efficacy we compared these parameters in children receiving conventional treatment only with those receiving octreotide. To analyze safety we compared the adverse effects of both treatments. Octreotide was administered at a dose of 4 to 10 microg/kg/hour, with monitoring of side effects. RESULTS: The incidence of chylothorax in our population was 1.6%. It occurred more often after Glenn and Fontan procedures (8 patients). Octreotide was begun three days after diagnosis of chylothorax and continued for a median of seventeen days (ranging from 4 to 26 days), until complete resolution. Side effects were frequent (in 3 of the 8 patients) but of no clinical relevance. All patients responded to the therapy and there was no indication for further surgical intervention. DISCUSSION AND CONCLUSIONS:
|
Authors | Filipa Paramés, Isabel Freitas, José Fragata, Conceição Trigo, Maria Fátima F Pinto |
Journal | Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
(Rev Port Cardiol)
2009 Jul-Aug
Vol. 28
Issue 7-8
Pg. 799-807
ISSN: 0870-2551 [Print] Portugal |
PMID | 19894659
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
|
Topics |
- Child
- Child, Preschool
- Chylothorax
(drug therapy)
- Female
- Heart Defects, Congenital
(surgery)
- Humans
- Infant
- Infant, Newborn
- Male
- Octreotide
(therapeutic use)
- Postoperative Complications
(drug therapy)
- Retrospective Studies
|